secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K/A
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001437749-23-017697
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech shareholders reject reverse stock split at adjourned annual meeting
--------------------------------------------------------------------------------

- Proposal No. 5 (reverse stock split) failed: 13,859,013 For, 5,349,509 Against, 161,035 Abstain.
- Only 65.60% of outstanding shares were represented at the reconvened meeting on June 15, 2023.
- No broker non-votes on the proposal; the amendment required stockholder approval.
- The board’s authority to effect a reverse split before the one-year anniversary was denied.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923017697/0001437749-23-017697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923017697/mbrx20230616_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-017697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer